1-methyl-3-isobutylxanthine has been researched along with Diabetes Mellitus, Type 2 in 10 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with IDDM had increased platelet aggregation (PA, expressed as microM ADP threshold concentration) before Rd was detectable in comparison to control subjects (P less than 0." | 1.27 | Platelet enzyme activities in diabetes mellitus in relation to endothelial damage. ( Janka, HU; Mehnert, H; Schramm, W; Standl, E, 1983) |
| "When mannoheptulose was introduced 15 min after starting perfusion with 27 mM glucose, inhibition was apparent in non-diabetic rats, but not in STZ." | 1.27 | B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia. ( Grill, V; Ostenson, CG; Westberg, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stumpf, I | 1 |
| Mühlbauer, E | 1 |
| Peschke, E | 1 |
| Janka, HU | 1 |
| Standl, E | 1 |
| Schramm, W | 1 |
| Mehnert, H | 1 |
| Kohnert, KD | 2 |
| Hehmke, B | 2 |
| Besch, W | 2 |
| Kessler, J | 1 |
| Klöting, I | 2 |
| Guenifi, A | 1 |
| Abdel-Halim, SM | 1 |
| Efendic, S | 1 |
| Ostenson, CG | 2 |
| Hou, X | 1 |
| Ling, Z | 1 |
| Quartier, E | 1 |
| Foriers, A | 1 |
| Schuit, F | 1 |
| Pipeleers, D | 1 |
| Van Schravendijk, C | 1 |
| Ahrén, B | 1 |
| Netherton, SJ | 1 |
| Jimmo, SL | 1 |
| Palmer, D | 1 |
| Tilley, DG | 1 |
| Dunkerley, HA | 1 |
| Raymond, DR | 1 |
| Russell, JC | 1 |
| Absher, PM | 1 |
| Sage, EH | 1 |
| Vernon, RB | 1 |
| Maurice, DH | 1 |
| Grill, V | 2 |
| Rundfeldt, M | 1 |
| Weir, GC | 1 |
| Leahy, JL | 1 |
| Bonner-Weir, S | 1 |
| Westberg, M | 1 |
1 review available for 1-methyl-3-isobutylxanthine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Arginine; Blood Glucose; Cyclic AMP; Diabete | 1986 |
9 other studies available for 1-methyl-3-isobutylxanthine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Brain; Cell Line, Tumor; Colforsin; Cyclic GMP; Cyclic Nucleot | 2008 |
Platelet enzyme activities in diabetes mellitus in relation to endothelial damage.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Diphosphate; Adenylyl Cyclases; Adolescent; Adult; Aged; beta | 1983 |
Impaired beta-cell function in the Chinese hamster CHIG/Han subline.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Blood Glucose; Cell Line; Cricetinae; Cricetulus; Diabetes Mel | 1995 |
Preserved initiatory and potentiatory effect of alpha-ketoisocaproate on insulin release in islets of glucose intolerant rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Cells, Cultured; Crosses, Genetic; Diabetes Mellitus, Type 2; | 1998 |
Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors.
Topics: 1-Methyl-3-isobutylxanthine; Amyloid; Animals; Blotting, Western; Cells, Cultured; Diabetes Mellitus | 1999 |
Insulin treatment improves islet function in type 2 diabetic Chinese hamsters.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Blood Glucose; Cricetinae; Cricetulus; Diabetes Mellitus, Type | 2001 |
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imi | 2002 |
Abnormalities of insulin responses after ambient and previous exposure to glucose in streptozocin-diabetic and dexamethasone-treated rats. Role of hyperglycemia and increased B-cell demands.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Blood Glucose; Dexamethasone; Diabetes Mellitus, Experimental; | 1986 |
B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia.
Topics: 1-Methyl-3-isobutylxanthine; Animals; B-Lymphocytes; Diabetes Mellitus, Experimental; Diabetes Melli | 1987 |